We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

"WB-DCE-MRI" in Multiple Myeloma as an Independent Prognostic Factor for Disease-free Survival (EVALICEMM)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01171430
Recruitment Status : Active, not recruiting
First Posted : July 28, 2010
Last Update Posted : November 6, 2017
Sponsor:
Information provided by (Responsible Party):

Study Description
Brief Summary:
The main objective of this study is to examine if absence of a satisfactory response on DCE-WB-MRI (see MR criteria of responders section) after completion of HDT followed by autologous stem-cell transplantation (ASCT) is an independent prognostic factor for EFS in patients with MM, compared with established ones including beta2-microglobulin and cytogenetic abnormalities. Secondary objectives are to examine if the microcirculation parameters obtained from baseline DCE-WB-MRI have prognostic significance and to examine if early DCE-WB-MRI performed after the induction HDT and before ASCT might also provide independent prognostic information for patient outcome, which might help in patient stratification and be integrated into the response criteria in the future.

Condition or disease Intervention/treatment
Multiple Myeloma Device: Whole Body Dynamic Contrast Enhanced MRI (WB-DCE-MRI)

  Show Detailed Description

Study Design

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 104 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Assessment of Dynamic Contrast Enhanced Whole Body MRI (DCE-WB-MRI) as Independent Prognostic Factor for Disease-free Survival in Multiple Myeloma (After Intensification Therapy and Autologous Stem Cell Transplantation Suppressed by Amendment n°3)
Actual Study Start Date : July 2010
Primary Completion Date : February 2016
Estimated Study Completion Date : February 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Multiple Myeloma
U.S. FDA Resources

Arms and Interventions

Arm Intervention/treatment
Experimental: MRI WHOLE BODY Device: Whole Body Dynamic Contrast Enhanced MRI (WB-DCE-MRI)

3 Whole Body Dynamic Contrast Enhanced MRI:

  • 1 WB-DCE-MRI before induction of chemotherapy(initial MRI).
  • 1 WB-DCE-MRI after induction high dose therapy and before intensification of chemotherapy and auto-transplant of hematopoietic sterns cells (early MRI).
  • 1 WB-DCE-MRI 3 months after treatment whatever (amendment n°3) (delayed MRI).
Other Name: Mult.Myeloma eligible for Autologous Stem Cell Transpl.


Outcome Measures

Primary Outcome Measures :
  1. Maximal percentage of bone marrow measurement on last WB DCE MRI [ Time Frame: Measurements will be performed on initialWB DCE MRI Examination. Follow-up = Five year ]
    Bone marrow enhancement : Enhancement (%) = (SIpost - SIpre) x 100/SIpre, where SIpre is the signal intensity before injection and SIpost is the signal intensity after injection


Secondary Outcome Measures :
  1. Maximal percentage of bone marrow measurement on initial WB DCE MRI [ Time Frame: Measurements will be performed on initialWB DCE MRI Examination. Follow-up = Five year ]
    Bone marrow enhancement : Enhancement (%) = (SIpost - SIpre) x 100/SIpre, where SIpre is the signal intensity before injection and SIpost is the signal intensity after injection


Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patient referred to one of the hematology departement associated with the research project, with confirmed multiple myeloma defined according to uniform international criteria.
  • Whatever stage classification according to Salmon and Durie with a life expectancy of more than 3 months.
  • Age under 70 years old (amendment n°5) and eligible for autologous stem cell transplantation.
  • Free and informed consent.

Exclusion Criteria:

  • Patient unfit physically, mentally or legally to give informed consent.
  • Patient non affiliate with social security scheme
  • Patient with myeloma without measurable monoclonal immunoglobulin, including measurement of serum free light chains.
  • Patient with another malignancy excluding basal cell cancer.
  • Patient who could not undergo MRI (incompatible metallic foreign body, pacemaker, allergy to contrast, claustrophobia despite premedication, pregnancy, renal failure with creatinine clearance <30 ml/min
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01171430


Locations
France
Henri Mondor Hospital
Creteil, France, 94010
Sponsors and Collaborators
Assistance Publique - Hôpitaux de Paris
Investigators
Principal Investigator: Alain Luciani Assistance Publique - Hôpitaux de Paris
More Information

Responsible Party: Assistance Publique - Hôpitaux de Paris
ClinicalTrials.gov Identifier: NCT01171430     History of Changes
Other Study ID Numbers: P081236
First Posted: July 28, 2010    Key Record Dates
Last Update Posted: November 6, 2017
Last Verified: November 2017

Keywords provided by Assistance Publique - Hôpitaux de Paris:
multiple myeloma
Autologous Stem Cell Transplantation

Additional relevant MeSH terms:
Multiple Myeloma
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Neoplasms
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Paraproteinemias
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases